The public-private partnership which is supported by 22 companies, NAIST, RIKEN and many universities will organize a collaborative screening consortium (drug-discovery innovation and screening consortium, DISC) based on 200,000 compounds from these companies. One aspect will also be to develop drugs for rare diseases.
AMED news release, December 24, 2015
Japanese Agency for Medical R&D (AMED) holds launch ceremony